Xilio Therapeutics, Inc.
A biotechnology company developing tumor-selective drugs designed to localize activity within the tumor microenvironment. Using its proprietary platform, the company is developing XTX101, an anti-CTLA-4 monoclonal antibody for patients with advanced solid tumors, and is also engaged in research collaborations and supply agreements with other companies. The company is based in Delaware.
Overview
Overview | |
|---|---|
Country | United States |
State | Massachusetts |
Employees | 56 |
Founded | 2016 |
Financials | |
|---|---|
Market Capitalization | 37.65M |
Revenue | |
Operating Income | -73.09M |
Operating Margin | |
Net Income | -70.96M |
Ranking
Operating Income
Operating Income Ranking | |
|---|---|
All | 4642 / 5373 |
Sector : Healthcare | 808 / 1144 |
Industry : Biotechnology | 388 / 645 |
Market Capitalization
Market Capitalization Ranking | |
|---|---|
All | 4684 / 5565 |
Sector : Healthcare | 861 / 1182 |
Industry : Biotechnology | 479 / 670 |
Net Income
Net Income Ranking | |
|---|---|
All | 4552 / 5436 |
Sector : Healthcare | 812 / 1164 |
Industry : Biotechnology | 402 / 659 |
Employees
Employees Ranking | |
|---|---|
All | 4369 / 5330 |
Sector : Healthcare | 776 / 1174 |
Industry : Biotechnology | 355 / 667 |